Proactive Investors - Run By Investors For Investors

Sativa in talks with beverage firms to create CBD drinks in the UK

Sativa boss Geremy Thomas expects the company to see a “big revenue uptick” from the new CBD products its George Botanicals unit is creating
Cannabis
Sativa says the UK cannabis market has a long way to go but it is making progress

Cannabis firm Sativa Group PLC (NEX:SATI) is in talks with beverage companies to make cannabidiol (CBD) drinks for UK consumers. 

The company’s manufacturing and distribution business, George Botanicals, has created a water-soluble CBD emulsion that can be added to food and drinks.

Geremy Thomas, the chief executive of Sativa, told Proactive Investors he has been in discussions with beverage companies he could not name yet to incorporate the emulsion into drinks.

READ: Sativa says 2019 first quarter revenues exceeding total revenues in the group’s first year of trading

“CBD products are mainly oil based but putting oils in water is difficult so we’ve made an emulsion that we can sell into the food and drinks industry,” he said.

Thomas expects the company to see a “big revenue uptick” from the new CBD products George Botanicals is developing.

George Botanicals' products currently include oils, balms, capsules and liquid additives for e-cigarettes.

The products are available online and at Sativa’s newly opened CBD retail store, Goodbody Wellness, in Bath.  

Sativa to roll out 100 CBD wellness stores 

Sativa opened the Bath store last Friday evening and plans to open 100 stores in the next two years. The next two stores will be opened in Cirencester and Bristol.

Thomas said the Bath store has already experienced strong demand in its first week of operation.

READ: Sativa opens first CBD wellness store with trading ahead of expectations

“Customers really liked the experience and bought more than we thought they would and I think that’s very encouraging,” he said.

While the roll out of 100 stores in two years may seem like an ambitious target, Thomas sees an opportunity to tap into a market that is expected to be worth £300mln in the UK this year and £1bn by 2025.

Thomas said the company plans to use its advantage as the UK’s first medical cannabis firm and get ahead of the game before rivals enter the scene.

New name to reflect new strategy 

The company listed on the NEX exchange as Sativa Investments in 2017 but has since changed its name to Sativa Group to reflect a change in the business model in response to the legalisation of medicinal marijuana in the UK last November.

Sativa was formed as an investment vehicle that put money into other medicinal cannabis firms. But it has since transformed into a trading company with three UK businesses including George Botanicals, Goodbody Wellness and medicinal cannabis research facility PhytoVista Laboratories.

“We have three trading businesses that are growing fast and generating real revenues from real customers who are repurchasing our products because they are happy with it,” Thomas said.

Last month Sativa said revenue in the first quarter of 2019 had exceeded the amount generated in its first year of trading.

Thomas said the group has continued to trade strongly and is optimistic about delivering robust results for the full year.

“I’m an old fashioned businessman that likes to have revenue, customers and growth and that’s what we’ve been focusing on,” he said.

London 'waking up' to potential of cannabis market 

He admits the UK market still has a long way to go as doctors are still reluctant to prescribe medicinal cannabis to patients despite the change in rules.

However, he expects medicinal cannabis will become an “important and sizeable” sector in the UK given the growth seen in America, Canada and Germany as well as the fact that a number of companies have been looking to list in London. 

“The city is waking up to that and think we’ll see more and more quality companies coming to the market but we’re just keen to keep our first mover advantage in place,” he said.

He added: “There’s upward pressure from our patients, downward pressure from our senior politicians and the bit in the middle has to get their act together and that’s a process….but we’re seeing more and more progress.”

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full SATI profile View Profile

Sativa Group PLC Timeline

Related Articles

LX2 analyzer
May 07 2019
Armed with promising study results and proven technology, LexaGene is getting ready to launch the LX2 Genetic Analyzer to underserved markets valued at an estimated US$40 billion
pills
April 12 2019
The biotechnology company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic naproxen use
man pointing to brain
April 25 2019
Brain Scientific’s EEG technology is far cheaper and less bulky than a traditional EEG system, but provides EEG tracings of the same quality

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use